Secretin-Ferring

(Secretin)

ApprovedSmall molecule

Ferring

Secretin-Ferring is one of 57 small molecule programs targeting Chronic Pancreatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Chronic PancreatitisActive, not recruiting

Pancreatic CancerActive, not recruiting

BiomarkersEnrolling by invitation

Chronic PancreatitisPreclinical

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

BiomarkersApproved

Enrolling by invitation

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Secretin-Ferring

Ferring

Approved

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Preclinical

1 10

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Cancer of the Pancreas

NCT02000089

Clinical

Trials by Indication[1]

Pancreatic4 trials

Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.

Unknown status·FFundacion Clinic per a la Recerca Biomédica·Phase 3·NCT05914077·140 enrolled

Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers

Completed·UUniversity of Nottingham·Phase 1·NCT01452217·12 enrolled

Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection

Completed·—·Phase 2/3·NCT02160808·170 enrolled

Show 1 more trial

Pancreatic Perfusion Using Secretin and MRI

Unknown status·UUniversity of Nottingham·Phase 1/2·NCT02458118·15 enrolled

Neostigmine1 trial

A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers

Completed·UUniversity of Nottingham·Phase 4·NCT01134848·10 enrolled

Biomarkers1 trial

Imaging Biomarkers of Pancreatic Function and Disease

Enrolling by invitation·—·Phase 4·NCT05659147·195 enrolled

Cancer of the Pancreas1 trial

The Cancer of the Pancreas Screening-5 CAPS5)Study

Recruiting·JJohns Hopkins University·Phase 3·NCT02000089·9,000 enrolled

Acute Pancreatitis1 trial

Secretin for Acute Pancreatitis

Unknown status·CChiRhoClin, Inc.·Phase 2·NCT03686618·40 enrolled

4 more indications

Schizophrenia1 trial

Effects of RG1068 (Secretin) on Information Processing in Schizophrenia

Completed·IIndiana University School of Medicine·Phase 2·NCT00235274·30 enrolled

Pancreatic Cancer1 trial

Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection

Withdrawn·EElizabeth Hecht·N/A·NCT01094626

Chronic Pancreatitis1 trial

MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics

Completed·—·N/A·NCT02869893·57 enrolled

Homeostasis1 trial

The Role of Secretin on the Energy Homeostasis

Completed·SSteno Diabetes Center Copenhagen·N/A·NCT04613700·25 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

SECRETIN-FERRING

NDA NDA018290

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Secretin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Secretin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Secretin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018290). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Ferring

Secretin-Ferring

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Pancreatic4 trials

Neostigmine1 trial

Biomarkers1 trial

Cancer of the Pancreas1 trial

Acute Pancreatitis1 trial

Schizophrenia1 trial

Pancreatic Cancer1 trial

Chronic Pancreatitis1 trial

Homeostasis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News